How Gene Variations Affect Weight-Loss Drug Efficacy

Researchers have identified genetic variants that may explain the significant variability in how patients respond to glucagon-like peptide-1 (GLP-1) receptor agonist medications used for obesity treatment. The findings, published in the journal Nature on April 8, 2026, suggest that variations in genes involved in gut hormone pathways influence both the efficacy of weight loss and the risk of gastrointestinal side effects.

The study analyzed data from 27,885 individuals who used the DNA-testing service 23andMe and reported taking GLP-1 receptor agonist therapy. This class of medication includes drugs such as semaglutide and tirzepatide, which mimic natural hormones to regulate appetite, insulin release, and digestion.

Genetic Predictors of Weight Loss Efficacy

The genome-wide association study identified a specific missense variant in the GLP1R gene that is significantly associated with increased medication efficacy. Specifically, the variant rs10305420 is linked to greater weight loss in individuals who carry it compared to those who do not.

According to the research, each copy of the effect allele is associated with an additional expected weight loss of 0.76 kg. While this provides direct genetic evidence that variation in drug target genes contributes to inter-person variability, some experts note that the genetic effect on overall weight loss is relatively small.

Associations with Treatment Side Effects

Beyond efficacy, the study found that genetic variations in both GLP1R and GIPR are linked to treatment-related nausea or vomiting. One specific variant, rs1800437, was associated with these gastrointestinal side effects in people taking tirzepatide, though it did not correlate with the amount of weight those patients lost.

The researchers noted that the association between GIPR variation and side effects was restricted to those using tirzepatide. Tirzepatide differs from semaglutide in that it mimics both GLP-1 and the glucose-dependent insulinotropic polypeptide (GIP) hormone.

Clinical Context and Precision Medicine

Obesity is a chronic condition affecting approximately 40% of adults in the United States, increasing the risk of cardiovascular disease and type 2 diabetes. Until the development of GLP-1 receptor agonists, therapeutic strategies were largely limited to lifestyle interventions such as diet, and exercise.

The wide variation in patient response is well-documented; for example, in one study of semaglutide users, some participants lost more than 25% of their body weight, while others lost almost none. The 23andMe research institute aims to use these findings to develop a broader model of medication response to stratify patients by efficacy and side effect risk.

There’s a number of factors that can influence weight loss, of which genetics is a subcomponent.

Adam Auton, vice-president of human genetics at 23andMe Research Institute

Despite the potential for precision medicine, some scientists remain cautious about immediate clinical application. Andrea Ganna, a health data scientist at the University of Helsinki, stated that because the genetic effect on weight loss is relatively small, he does not see it as something clinicians will currently use to inform their practice.

However, the association between genetics and side effects was described as more substantial, suggesting that genetic screening may be more immediately useful for predicting adverse reactions than for predicting total weight loss.